Glucagon-like peptide-1 (GLP-1) receptor agonists like Semaglutide, Tirzepatide, and Retatrutide have revolutionized the treatment of type 2 diabetes and obesity. However, the higher doses often prescribed can sometimes lead to unpleasant side effects. Enter the concept of microdosing, a practice that involves taking smaller, more frequent doses of these medications. This approach has been gaining […]

Glucagon-like peptide-1 (GLP-1) is a hormone that plays a key role in blood sugar regulation1. It stimulates the release of insulin, reduces the release of glucagon (a hormone that raises blood sugar), and slows down digestion1. This promotes a feeling of fullness and may help with weight management1. Certain foods can naturally increase GLP-1 levels.

Peptides, short chains of amino acids, have become a significant focus in scientific research due to their potential in understanding biological processes, exploring potential drug targets, and advancing our knowledge of diseases. However, the use of peptides is not without regulatory oversight. The U.S. Food and Drug Administration (FDA) has implemented restrictions on certain peptides,

Retatrutide: Is it better than Ozempic and Mounjaro? In the world of weight management, three drugs have been making waves: Retatrutide, Semaglutide, and Tirzepatide. Each of these drugs has shown promise in clinical trials, but how do they stack up against each other? Let’s dive in. RetatrutideRetatrutide is an experimental drug developed by Eli Lilly